Helen Tremlett

Dr Tremlett’s research program is funded through operating and foundation grants from the Canadian Institutes of Health Research (CIHR), the MS Society of Canada, the MS Scientific Research Foundation, the US National MS Society among others. Trained in pharmacoepidemiology and multiple sclerosis with a PhD from Cardiff University, UK. Heads the Tremlett Lab and the Epidemiology in Multiple Sclerosis (MS) research program with the vision of fostering excellence in multi-disciplinary clinical and epidemiological research to advance treatment-related knowledge and improve outcomes in those with MS. Ongoing research studies include: the MS prodrome, safety and effectiveness of the disease-modifying drugs for MS; pharmacogenomics; risk of MS in special populations; impact of comorbidities on MS outcomes; and the gut microbiome and MS.